Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

Hot Topics

ODYSSEY OUTCOMES: impact on hospitalisation

Prof. Anthony Wierzbicki, Guy's & St Thomas' Hospitals, London, UK discusses this analysis evaluating the impact of PCSK9 inhibition on hospitalisation following ACS

Read the report
Other related reports:
AHA 2018 ODYSSEY OUTCOMES Total Events Analysis
View the video
PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
View the video
FOURIER: Evolocumab reduced the burden of total cardiovascular events
Read the report

From the Editors

PCSK9 inhibition, low LDL cholesterol and lack of cognitive impairment: QED?

Prof Derick Raal, University of the Witwatersrand, Johannesburg, South Africa, discusses the latest data from FOURIER regarding cognitive safety. What is the take home message for clinicians?

Read the report

 

Other related reports:
Low LDL-C and cognitive function: Benefit or harm?
Watch the webcast
Do the PCSK9 monoclonal antibodies have neurocognitive effects
Watch the video
PCSK9 inhibition and neurocognitive effects:Weighing up the evidence
Read the report

ACC 2017

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology